Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trialCRITICAL CAREIF9.32022-11-1532OAAI
Performance of the Cepheid Methicillin-Resistant Staphylococcus aureus/S. aureus Skin and Soft Tissue Infection PCR Assay on Respiratory Samples from Mechanically Ventilated Patients for S. aureus Screening during the Phase 2 Double-Blind SAATELLITE StudyJOURNAL OF CLINICAL MICROBIOLOGYIF5.42022-07-204OA
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trialLANCET INFECTIOUS DISEASESIF312021-09-0155OAAI
Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adultsCLINICAL MICROBIOLOGY AND INFECTIONIF8.52019-05-0190OAAI
Respiratory Syncytial Virus Genotypes, Host Immune Profiles, and Disease Severity in Young Children Hospitalized With BronchiolitisJOURNAL OF INFECTIOUS DISEASESIF4.52017-10-1780OAAI
Antibody-based therapy to combat Staphylococcus aureus infectionsCLINICAL MICROBIOLOGY AND INFECTIONIF8.52017-04-0113OAAI
Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy AdultsANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52017-01-01133OAAI
Staphylococcus aureus Alpha-Toxin Is Conserved among Diverse Hospital Respiratory Isolates Collected from a Global Surveillance Study and Is Neutralized by Monoclonal Antibody MEDI4893ANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52016-09-0154OAAI
The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial PneumoniaCLINICAL INFECTIOUS DISEASESIF7.32016-07-3120OAAI
Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trialLANCET INFECTIOUS DISEASESIF312015-12-01154PREAI
The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistanceJOURNAL OF ANTIMICROBIAL CHEMOTHERAPYIF3.62015-11-1599OA
Characterization of Alpha-Toxin hla Gene Variants, Alpha-Toxin Expression Levels, and Levels of Antibody to Alpha-Toxin in Hemodialysis and Postsurgical Patients with Staphylococcus aureus BacteremiaJOURNAL OF CLINICAL MICROBIOLOGYIF5.42015-01-0144OAAI
Serious Early Childhood Wheezing After Respiratory Syncytial Virus Lower Respiratory Tract Illness in Preterm InfantsCLINICAL THERAPEUTICSIF3.62010-12-0120PREAI
Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised ChildrenANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52010-10-01114OAAI
Effect of dexamethasone on respiratory syncytial virus-induced lung inflammation in children: results of a randomized, placebo controlled clinical trial地塞米松对儿童呼吸道合胞病毒诱发的肺部炎症的影响: 一项随机,安慰剂对照临床试验的结果PEDIATRIC ALLERGY AND IMMUNOLOGYIF4.52009-07-2246OAAI
Pharmacokinetics and Safety of Caspofungin in Older Infants and ToddlersANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52009-04-0164OAAI
Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of AgeANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52009-03-0199OAAI
A Prospective, Multicenter Study of Caspofungin for the Treatment of Documented Candida or Aspergillus Infections in Pediatric PatientsPEDIATRICSIF6.42009-03-0190PREAI
Infliximab Treatment of Intravenous Immunoglobulin-Resistant Kawasaki DiseaseJOURNAL OF PEDIATRICSIF3.52008-12-01207OAAI